XM does not provide services to residents of the United States of America.

Health of detained Binance executive deteriorates in Nigerian prison, wife says



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>Health of detained Binance executive deteriorates in Nigerian prison, wife says</title></head><body>

By Camillus Eboh

ABUJA, Aug 12 (Reuters) -The health of detained Binance executive, Tigran Gambaryan, has deteriorated in a Nigerian prison where he faces money laundering charges, his wife said on Monday.

Binance, the world's largest cryptocurrency exchange, and two of its executives - Gambaryan, a U.S. citizen and head of financial crime compliance, and Nadeem Anjarwalla, a British-Kenyan who is a regional manager for Africa - have been charged with laundering over $35 million.

In a separate charge, Binance is facing a case of tax evasion.

Both Binance and Gambaryan have denied the charges. Anjarwalla escaped custody and left Nigeria before the trial commenced.

"His health is in a shockingly bad condition and getting worse by the day," Gambaryan's wife, Yuki Gambaryan, said in a statement.

"The herniated disc in his back has worsened to the point where it might leave permanent damage and affect his ability to walk," Yuki Gambaryan's statement read.

She said her husband had been denied access to his lawyers since July 26.

The prison service, the Nigerian Correctional Service, did not respond to calls.

Binance said in March it would stop all transactions and trading in Nigeria's local currency following a country-wide crackdown on crypto exchanges that authorities have blamed for fuelling demand for U.S. dollars on the black market.

Trial judge Emeka Nwite ordered a medical report after Gambaryan appeared in court in Abuja in a wheelchair last month from Kuje maximum security prison located on the outskirts of the capital. But the medical report was not submitted, according to the court hearing.

The judge ordered that Gambaryan be admitted to a hospital for 24 hours for medical diagnosis and treatment.

He adjourned Gambaryan's trial to Oct. 11.



Reporting by Camillus Eboh
Editing by Chijioke Ohuocha and Ros Russell

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.